Investors bought shares of Eli Lilly and Co. (NYSE:LLY) on weakness during trading on Friday. $51.32 million flowed into the stock on the tick-up and $29.80 million flowed out of the stock on the tick-down, for a money net flow of $21.52 million into the stock. Of all companies tracked, Eli Lilly and had the 19th highest net in-flow for the day. Eli Lilly and traded down ($0.34) for the day and closed at $80.22

LLY has been the topic of several research analyst reports. TheStreet upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating in a report on Friday, May 27th. Jefferies Group boosted their price target on shares of Eli Lilly and from $100.00 to $105.00 and gave the stock a “buy” rating in a research note on Thursday, July 14th. Zacks Investment Research lowered shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Thursday, August 4th. Argus boosted their price target on shares of Eli Lilly and from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Tuesday, August 2nd. Finally, SunTrust Banks Inc. reiterated a “buy” rating on shares of Eli Lilly and in a research note on Wednesday, June 15th. Four equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $95.90.

The firm’s 50 day moving average price is $80.31 and its 200 day moving average price is $75.97. The stock has a market capitalization of $84.85 billion and a P/E ratio of 34.58.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 26th. The company reported $0.86 EPS for the quarter, meeting the consensus estimate of $0.86. The company had revenue of $5.40 billion for the quarter, compared to analysts’ expectations of $5.14 billion. The business’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.90 earnings per share. On average, equities analysts expect that Eli Lilly and Co. will post $3.59 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 9th. Investors of record on Monday, August 15th will be issued a dividend of $0.51 per share. The ex-dividend date of this dividend is Thursday, August 11th. This represents a $2.04 annualized dividend and a dividend yield of 2.54%.

In related news, SVP Melissa S. Barnes sold 992 shares of the firm’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $73.77, for a total transaction of $73,179.84. Following the sale, the senior vice president now directly owns 10,710 shares in the company, valued at approximately $790,076.70. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the firm’s stock in a transaction dated Tuesday, May 31st. The shares were sold at an average price of $75.12, for a total value of $15,024,000.00. Following the sale, the insider now owns 127,090,804 shares in the company, valued at $9,547,061,196.48. The disclosure for this sale can be found here.

Several large investors recently made changes to their positions in LLY. Parsons Capital Management Inc. RI increased its stake in shares of Eli Lilly and by 1.3% in the fourth quarter. Parsons Capital Management Inc. RI now owns 53,289 shares of the company’s stock valued at $4,490,000 after buying an additional 703 shares during the last quarter. Zweig DiMenna Associates LLC bought a new stake in shares of Eli Lilly and during the fourth quarter valued at approximately $11,375,000. Freestone Capital Holdings LLC increased its stake in shares of Eli Lilly and by 8.2% in the fourth quarter. Freestone Capital Holdings LLC now owns 27,594 shares of the company’s stock valued at $2,325,000 after buying an additional 2,099 shares during the last quarter. Suntrust Banks Inc. increased its stake in shares of Eli Lilly and by 16.8% in the fourth quarter. Suntrust Banks Inc. now owns 255,833 shares of the company’s stock valued at $21,554,000 after buying an additional 36,887 shares during the last quarter. Finally, Advantus Capital Management Inc increased its stake in shares of Eli Lilly and by 2.9% in the fourth quarter. Advantus Capital Management Inc now owns 94,250 shares of the company’s stock valued at $7,942,000 after buying an additional 2,631 shares during the last quarter.

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.